Editas Medicine (EDIT) will present updated safety and efficacy data in 28 patients living with severe sickle cell disease treated with ...
Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
Only one quarter of patients living with sickle cell disease are prescribed disease modifying therapies, particularly newer ...
The latest announcement is out from Beam Therapeutics ( (BEAM) ).
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
When you give to Light Up A Lawn, Light Up A Life, you are supporting programs like Nationwide Children's cutting-edge gene ...
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, ...
This results in red blood cells being destroyed, which is known as hemolytic anemia ... People with beta thalassemia trait will have elevation in hemoglobin A2 and/or F (fetal). There is no simple ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...
Beam Therapeutics (BEAM) announced new data for its Engineered Stem Cell Antibody Evasion, or ESCAPE, conditioning platform.
Johnson & Johnson today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and ...
A drug developed by Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder ...